top of page
TIRZEPATIDE
Tirzepatide glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists. It was originally developed and approved as a treatment for type 2 diabetes in conjunction with diet and exercise to improve glycemic control.
TIRZEPATIDE
Tirzepatide is also used to assist patients with Type 2 Diabetes and obesity in losing weight while improving cardiovascular diseases.
Tirzepatide is unique in its class of medications since it targets both the GIP and GLP-1 receptor agonists.
In research, the effectiveness of tirzepatide is not impacted by age, gender, race, ethnicity, region, or by baseline BMI, HbA1c, diabetes duration, or renal function.
bottom of page